About
What it is and where it shows up.
Bacillus coagulans is a spore-forming, lactic acid–producing gram-positive bacterium widely used as a probiotic food ingredient. Its heat- and acid-stable endospores survive food-processing conditions and gastric acidity that typically destroy conventional probiotic bacteria such as Lactobacillus species, enabling effective gut colonisation.
Safety summary
The regulatory and scientific consensus.
Multiple animal and human toxicological studies demonstrate no mutagenic, clastogenic, or genotoxic effects and a no-observed-adverse-effect level (NOAEL) exceeding 1,000 mg/kg/day. Genome-wide analyses across commercially important strains (GBI-30 6086, SNZ1969, MTCC 5856) confirm absence of toxin-encoding genes and no easily transferable antibiotic resistance elements. No ADI has been established since dosing is measured in colony-forming units (CFU); immunocompromised individuals should use caution as with all live probiotic organisms.
Regulatory landscape
What food-safety regulators have decided.
| Jurisdiction | Status | Note |
|---|---|---|
| EFSA (European Food Safety Authority) (European Union) | Approved | Qualified Presumption of Safety (QPS) status granted by the EFSA Scientific Committee in 2007 (EFSA Journal 587:1-16) and maintained through the 2025 BIOHAZ Panel review (latest QPS list published January 2026). EFSA recognises B. coagulans as non-pathogenic and non-toxicogenic. Qualification conditions: (1) absence of toxigenic potential including food-borne toxins and enterotoxins, and (2) absence of acquired antibiotic resistance genes of human/veterinary concern. Strain-level verification required for each application.source |
| FSSAI (Food Safety and Standards Authority of India) (India) | Approved | Permitted as a probiotic ingredient in health supplements and nutraceuticals under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, gazetted on 23 December 2016 and enforced from 1 January 2018. Commercially marketed in India under trade names including LactoSpore (Sanzyme Ltd.) and Sporlac. Use in novel food formats requires prior FSSAI approval under FSS (Approval for Non-Specified Food and Food Ingredients) Regulations, 2017.source |
| FDA (Food and Drug Administration) (United States) | Approved | Multiple GRAS notices filed and accepted: GRN 399 (GBI-30 6086, live spores), GRN 526, GRN 597 (SNZ1969), GRN 601 (MTCC 5856), GRN 660 (GBI-30 6086), GRN 670 (Inactivated GBI-30 6086), GRN 691 (SANK 70258), GRN 725 (Inactivated GBI-30 6086 in non-exempt term infant formula), GRN 864 (SNZ1969 in infant/toddler foods). Permitted in baked goods, beverages, cereals, chewing gum, confections, dairy analogs, snack foods, soups, and infant formula. Typical use level: 2×10⁹ CFU/serving. FDA has not questioned GRAS conclusions for any accepted notice. |
Who should approach with care
Whose guidance would steer them away.
Other — Immunocompromised individuals (e.g., transplant recipients, chemotherapy patients, HIV/AIDS) should use caution with all live probiotic bacteria including B. coagulans due to a theoretical risk of bacteraemia or opportunistic infection, consistent with standard probiotic clinical guidance; FDA's GRN 725 specifically restricted inactivated B. coagulans from immunocompromised infant populations.
Ibd — While B. coagulans is studied for GI benefits, individuals with active inflammatory bowel disease should consult a physician before use, as probiotic responses can vary and transient bloating or altered gut motility may be experienced during severe flares.
Infants — Although inactivated B. coagulans GBI-30 6086 has received FDA GRAS status for use in non-exempt term infant formula (GRN 725), live spore preparations in infants should be used only under medical supervision given the developing immune system and the need for strain- and formulation-specific safety data.
Research citations
The sources behind this verdict.
- 1FDA. Agency Response Letter GRAS Notice No. GRN 000399 – Bacillus coagulans GBI-30, 6086 (Ganeden Biotech). fda.gov
- 2EFSA. Qualified Presumption of Safety (QPS) – Updated List of QPS-Recommended Microorganisms Intentionally Added to Food or Feed (2025 update), 2026. efsa.europa.eu
- 3FDA. Agency Response Letter GRAS Notice No. GRN 000597 – Bacillus coagulans SNZ1969 Spores Preparation (Sanzyme Limited), 2018. fda.gov
- 4PubMed. Integrate genome-based assessment of safety for probiotic strains: Bacillus coagulans GBI-30, 6086 as a case study, 2016. pubmed.ncbi.nlm.nih.gov
- 5PubMed. Safety assessment of a proprietary preparation of a novel Probiotic, Bacillus coagulans, as a food ingredient, 2009. pubmed.ncbi.nlm.nih.gov
Independently researched5 citations